News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
844,934 Results
Type
Article (77414)
Company Profile (726)
Press Release (766774)
Multimedia
Podcasts (194)
Webinars (29)
Section
Business (228593)
Career Advice (3799)
Deals (39362)
Drug Delivery (151)
Drug Development (89774)
Employer Resources (205)
FDA (18161)
Job Trends (17218)
News (389719)
Policy (39043)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (3018)
Academic (2)
Accelerated approval (37)
Adcomms (36)
Allergies (154)
Alliances (56307)
ALS (184)
Alzheimer's disease (1815)
Antibody-drug conjugate (ADC) (361)
Approvals (18351)
Artificial intelligence (614)
Autoimmune disease (183)
Automation (42)
Bankruptcy (403)
Best Places to Work (12633)
BIOSECURE Act (23)
Biosimilars (209)
Biotechnology (450)
Bladder cancer (165)
Brain cancer (67)
Breast cancer (679)
Cancer (5164)
Cardiovascular disease (458)
Career advice (3257)
Career pathing (42)
CAR-T (315)
CDC (63)
Celiac Disease (2)
Cell therapy (848)
Cervical cancer (38)
Clinical research (75927)
Collaboration (1891)
Company closure (5)
Compensation (1210)
Complete response letters (78)
COVID-19 (2998)
CRISPR (105)
C-suite (931)
Cystic fibrosis (155)
Data (6460)
Decentralized trials (2)
Denatured (71)
Depression (157)
Diabetes (543)
Diagnostics (7270)
Digital health (52)
Diversity (13)
Diversity, equity & inclusion (49)
Drug discovery (297)
Drug pricing (226)
Drug shortages (36)
Duchenne muscular dystrophy (249)
Earnings (97894)
Editorial (67)
Employer branding (25)
Employer resources (174)
Events (134420)
Executive appointments (1057)
FDA (21440)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1591)
Gene editing (225)
Generative AI (62)
Gene therapy (688)
GLP-1 (1144)
Government (5437)
Grass and pollen (8)
Guidances (388)
Healthcare (20950)
HIV (69)
Huntington's disease (51)
IgA nephropathy (88)
Immunology and inflammation (306)
Immuno-oncology (66)
Indications (116)
Infectious disease (3304)
Inflammatory bowel disease (212)
Inflation Reduction Act (17)
Influenza (128)
Intellectual property (263)
Interviews (745)
IPO (17860)
IRA (61)
Job creations (4985)
Job search strategy (2633)
JPM (71)
Kidney cancer (17)
Labor market (97)
Layoffs (657)
Leadership (42)
Legal (9973)
Liver cancer (99)
Longevity (15)
Lung cancer (699)
Lymphoma (390)
Machine learning (44)
Management (66)
Manufacturing (883)
MASH (179)
Medical device (15045)
Medtech (15104)
Mergers & acquisitions (22597)
Metabolic disorders (1438)
Multiple sclerosis (173)
NASH (23)
Neurodegenerative disease (370)
Neuropsychiatric disorders (106)
Neuroscience (3185)
Neurotech (1)
NextGen: Class of 2026 (7659)
Non-profit (5120)
Now hiring (68)
Obesity (702)
Opinion (341)
Ovarian cancer (172)
Pain (219)
Pancreatic cancer (242)
Parkinson's disease (304)
Partnered (37)
Patents (533)
Patient recruitment (520)
Peanut (61)
People (65888)
Pharmaceutical (134)
Pharmacy benefit managers (33)
Phase 1 (23480)
Phase 2 (33080)
Phase 3 (24944)
Pipeline (5572)
Policy (345)
Postmarket research (3282)
Preclinical (10366)
Press Release (72)
Prostate cancer (254)
Psychedelics (60)
Radiopharmaceuticals (308)
Rare diseases (957)
Real estate (7212)
Recruiting (81)
Regulatory (28493)
Reports (69)
Research institute (2733)
Resumes & cover letters (592)
Rett syndrome (28)
RNA editing (21)
RSV (88)
Schizophrenia (162)
Series A (265)
Series B (204)
Service/supplier (27)
Sickle cell disease (106)
Special edition (28)
Spinal muscular atrophy (177)
Sponsored (49)
Startups (4238)
State (2)
Stomach cancer (20)
Supply chain (115)
Tariffs (101)
The Weekly (121)
Vaccines (1180)
Venture capital (101)
Weight loss (482)
Women's health (95)
Worklife (22)
Date
Today (201)
Last 7 days (671)
Last 30 days (2511)
Last 365 days (32420)
2026 (4137)
2025 (32661)
2024 (37920)
2023 (42566)
2022 (53928)
2021 (58722)
2020 (57665)
2019 (51315)
2018 (39096)
2017 (36855)
2016 (37798)
2015 (43820)
2014 (38559)
2013 (34694)
2012 (36545)
2011 (36601)
2010 (36143)
Location
Africa (1218)
Alabama (92)
Alaska (7)
Arizona (327)
Arkansas (14)
Asia (50036)
Australia (8586)
California (11860)
Canada (3392)
China (1204)
Colorado (503)
Connecticut (515)
Delaware (355)
Europe (114161)
Florida (1757)
Georgia (381)
Hawaii (4)
Idaho (67)
Illinois (973)
India (74)
Indiana (558)
Iowa (24)
Japan (451)
Kansas (134)
Kentucky (44)
Louisiana (30)
Maine (84)
Maryland (1479)
Massachusetts (8700)
Michigan (365)
Minnesota (675)
Mississippi (6)
Missouri (143)
Montana (36)
Nebraska (29)
Nevada (128)
New Hampshire (86)
New Jersey (3184)
New Mexico (33)
New York (3131)
North Carolina (1644)
North Dakota (10)
Northern California (5715)
Ohio (361)
Oklahoma (23)
Oregon (53)
Pennsylvania (2364)
Puerto Rico (25)
Rhode Island (51)
South America (1584)
South Carolina (68)
South Dakota (1)
Southern California (4588)
Tennessee (182)
Texas (1854)
United States (42646)
Utah (355)
Vermont (1)
Virginia (298)
Washington D.C. (88)
Washington State (989)
West Virginia (4)
Wisconsin (134)
Wyoming (2)
844,934 Results for "jenapharm gmbh and co kg".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
February 2, 2026
·
9 min read
Press Releases
Independent Data Monitoring Committee Recommends Initiation of Cohort 2 at the Increased Dose of 12 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study
February 17, 2026
·
6 min read
Press Releases
Model Medicines to Present Evidence of First Direct-Acting Antiviral Potent Against HCV, HBV, HDV, and Co-Infections at CROI 2026
Over 300 million patients are infected with HCV, HBV, HDV, and their co-infections. MDL-001 is the first oral small molecule to demonstrate potent, direct-acting antiviral activity across all three viruses and their co-infections.
February 18, 2026
·
1 min read
Press Releases
BioNxt Signs Letter of Intent with Gen-Plus GmbH & Co KG for Potential Business Collaborations
August 15, 2024
·
3 min read
Press Releases
Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive Positive CHMP Opinion for an Additional Dosing Regimen of 2mg/kg Body Weight Every-Four-Weeks for Elfabrio® (pegunigalsidase alfa) ▼ in the EU
February 1, 2026
·
9 min read
Deals
Luciole Medical AG Announces the Acquisition of Spiegelberg GmbH & Co. KG to Create a Leading Global Brain Monitoring Developer and Provider
Luciole Medical AG, a Swiss medical technology company specialized in brain monitoring, announced the acquisition of Spiegelberg GmbH & Co. KG, an established medical device company and provider of highly specialized devices and consumables for neurosurgery, from SHS Capital.
June 27, 2023
·
4 min read
Press Releases
STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs
February 2, 2026
·
3 min read
Press Releases
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
November 5, 2025
·
3 min read
Genetown
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG (Medice – The Health Family), for Medice to market Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by Akebia to treat anemia due to chronic kidney disease (CKD), in Europe.
May 25, 2023
·
7 min read
Press Releases
Croma-Pharma GmbH Enters Strategic Distribution Partnership with Renellence in Canada
October 10, 2025
·
2 min read
1 of 84,494
Next
